Evaluation of an eXtended and proacTive Dosing regimEn in Treatment-Naïve Patients With Wet Age-related Macular Degeneration (wAMD)

CompletadoClinicalTrials.gov

ID: NCT03939767Tipo: OBSERVATIONALInicio: 12 de may de 2019Fin estimado: 17 de oct de 2023

Traducción no disponible, mostrando original

Resumen

In this observational study researchers want to learn more about changes in visual acuity (clarity of vision) with proactive flexible treatments over time in patients suffering from wet age-related macular degeneration (wAMD) after decision to treat with Aflibercept (Eylea) was made. Wet AMD is an eye disease that progressively destroys the macula, the central portion of the retina, impairing central vision.

Elegibilidad

Edad mínima: 50 YearsSexo: ALL

Criterios de inclusión

A diagnosis of wAMD.
Patients for whom the decision to initiate treatment with IVT aflibercept in a proactive regimen was made as routine clinical practice.
Treatment-naïve in the study eye (no prior therapy for wAMD).
Patient age ≥50 years of age.
Written informed patient consent before the start of data collection (according to the requirements of the local authorities and laws).

Criterios de exclusión

Participation in an investigational program with interventions outside of routine clinical practice.
Patients with contraindications to IVT aflibercept listed in the local marketing authorization.
Planned treatment regimen outside of the local marketing authorization.
Patients with eye diseases, e.g. advanced glaucoma or visually significant cataracts, likely to require surgery during the observation period in the study eye.
Concomitant ocular or systemic administration of drugs up to 3 months before IVT aflibercept treatment that could interfere with or potentiate the mechanism of action of IVT aflibercept, including other anti-VEGF agents in the fellow eye.
Any other retinal disease which may interfere with the treatment of wAMD.

Intervenciones

drug

Aflibercept (Eylea, BAY86-5321)

As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.

Ubicaciones

Many Locations

Multiple Locations, Argentina

Patrocinadores

PrincipalBayer

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

Evaluation of an eXtended and proacTive Dosing regimEn in... | EligiMed